Výsledky vyhledávání - Peter Vandenberghe

Upřesnit hledání
  1. 1
    Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia

    Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia Autor Els Lierman, Dominik Selleslag, Sanne Smits, Johan Billiet, Peter Vandenberghe

    Vydáno 2012
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  2. 2
    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) Autor Bartosz Wasąg, Els Lierman, Mira Meeus, Jan Cools, Peter Vandenberghe

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model

    CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model Autor Stefaan W. Van Gool, Peter Vandenberghe, Mark de Boer, Jan Ceuppens

    Vydáno 1996
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases Autor Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

    Vydáno 2012
    Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  5. 5
    The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines

    The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines Autor Jan Delabie, Jan Ceuppens, Peter Vandenberghe, Mark de Boer, Lieve Coorevits, Chris Peeters

    Vydáno 1993
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation

    Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation Autor Katherine Vandenborre, Stefaan W. Van Gool, Ahmad Kasran, Jan Ceuppens, M. Boogaerts, Peter Vandenberghe

    Vydáno 1999
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances

    Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances Autor Sabine Franke, Iwona Włodarska, Brigitte Maes, Peter Vandenberghe, Jan Delabie, Anne Hagemeijer, Chris De Wolf‐Peeters

    Vydáno 2001
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern Autor José Luis Ferreiro, Julie Morscio, Daan Dierickx, Lukas Marcelis, G. Verhoef, Peter Vandenberghe, Thomas Tousseyn, Iwona Wlodarska

    Vydáno 2015
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

    Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data Autor Gils Roex, Tom Feys, Yves Béguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille

    Vydáno 2020
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

    Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for I... Autor Johan Maertens, Jan Verhaegen, Hilde Demuynck, Penelope Brock, Gregor Verhoef, Peter Vandenberghe, Johan Van Eldere, L. Verbist, Marc Boogaerts

    Vydáno 1999
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features

    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features Autor José Luis Ferreiro, Julie Morscio, Daan Dierickx, Peter Vandenberghe, Olivier Gheysens, G. Verhoef, M. Zamani, Thomas Tousseyn, Iwona Włodarska

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

    Can positron emission tomography with [<sup>18</sup>F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others... Autor Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, José Thomas, Peter Vandenberghe, Jan Balzarini, Christine De Wolf‐Peeters, Luc Mortelmans, Gregor Verhoef

    Vydáno 2001
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation Autor Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dębiec‐Rychter

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes

    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes Autor Michel Delforge, H Demuynck, Peter Vandenberghe, G. Verhoef, Pierre Zachée, V. Van Duppen, P Marijnen, Herman Van den Berghe, MA Boogaerts

    Vydáno 1995
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant Autor Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

    Vydáno 2006
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis

    B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis Autor Zhanju Liu, Karel Geboes, Peter W. Hellings, Philippe Maerten, Hubertine Heremans, Peter Vandenberghe, Louis Boon, Peter van Kooten, Paul Rutgeerts, Jan Ceuppens

    Vydáno 2001
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma Autor Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, José Thomas, Tjibbe de Groot, Jan Balzarini, C. De Wolf‐Peeters, L. Mortelmans, G. Verhoef

    Vydáno 2002
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas

    Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas Autor Iwona Włodarska, Daan Dierickx, Vera Vanhentenrijk, Katrien Van Roosbroeck, H Pospíšilová, Francesca Minnei, Gregor Verhoef, José Thomas, Peter Vandenberghe, Chris De Wolf‐Peeters

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia Autor Kim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, Cedric Folens, Leander Van Neste, Sofie Bekaert, Peter Vandenberghe, María D. Odero, Peter Marynen, Jan Cools

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions Autor Katrien Van Roosbroeck, Jan Cools, Daan Dierickx, José Thomas, Peter Vandenberghe, Michel Stul, Jan Delabie, Chris De Wolf‐Peeters, Peter Marynen, Iwona Włodarska

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: